A Randomized Controlled Double-Blind Trial of Fentanyl Nasal Spray (Lazanda) Plus Hydromorphone Demand PCA Versus Placebo Nasal Spray Plus Hydromorphone Demand PCA for Treatment of Breakthrough Cancer Pain in the Emergency Department
Phase of Trial: Phase IV
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Fentanyl (Primary) ; Hydromorphone
- Indications Cancer pain
- Focus Therapeutic Use
- 18 Jan 2017 Status changed from suspended to discontinued.
- 09 Feb 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.
- 09 Feb 2015 Status changed from discontinued to suspended as reported by ClinicalTrials.gov.